ArticleBMC public health2025
Economic burden of Type 2 diabetes in Iran in 2022.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Delphi consensus validation of an integrated climate sensitive diabetes management model for climate vulnerable health systems in Iran.Scientific reports · 2026Article
- Development, Suitability and Comprehensibility of a QR Code-Enabled Educational Package to Improve Self-Care Practices Among Patients With Type 2 Diabetes: A Multimethod Study in Iran.Health expectations : an international journal of public participation in health care and health policy · 2026Article
- Galectins: Role and Therapeutics in Diabetes and Diabetic Foot Ulcers.Biomolecules · 2026Review
- Effects of a Nurse-Led Diabetes Perception Intervention Delivered via a Mobile Messaging Platform (LINE) on Glycemic Control and Patient Outcomes Among Adults with Diabetes and Poorly Controlled Glucose: A Randomized Controlled Trial.Journal of multidisciplinary healthcare · 2026Article
- Cost-Effectiveness analysis of insulin therapies for patients with type 2 diabetes in Iran: a long-term analysis using the UKPDS model.Journal of diabetes and metabolic disorders · 2025Article
- Cost effectiveness analysis of six non insulin agents for type 2 diabetes in Iran using a patient level simulation with UKPDS OM2.Scientific reports · 2025Article
- Design and validation of the Disaster Health Literacy Questionnaire for diabetes patients in Iran: a mixed-methods study.BMJ open · 2025Article
- Plant-Based Diets and Cardiometabolic Diseases in a Cohort of Iranian Adults: A Systematic Review of Evidence from the Tehran Lipid and Glucose Study.International journal of endocrinology and metabolism · 2025Article
- Ambient Air Pollution and Cardiometabolic Health in the Tehran Lipid and Glucose Study: A Scoping Review of Two Decades of Evidence.International journal of endocrinology and metabolism · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes mellitus, particularly Type 2 diabetes (T2D), represents a significant global health challenge, with its prevalence steadily rising over the past few decades. This study was conducted with the aim of estimating the economic burden of T2D in Iran.
methodsThis study employed a prevalence-based approach to estimate the economic burden of T2D and its attributable complications in adults above 20 years old in Iran for 2022. Both direct medical costs and indirect costs were considered in our analysis. Direct medical costs included inpatient and outpatient costs attributable to T2D and its complications, while indirect costs encompassed absenteeism, presenteeism, inability to work, and premature mortality costs due to the disease.
resultsThe findings showed that a total of 5,702,547 people, equivalent to 14.2% of Iranian adults, had T2D. The estimated total direct medical cost of T2D and its attributable complications in Iran in 2022 was 1,879.2 million US dollars (US$-PPP 6,676.9 million). Chronic kidney disease accounted for the largest proportion, followed by ischemic heart disease (IHD), and T2D itself. The total economic burden of T2D and its attributable complications in Iran in 2022, was estimated to be $2,905.7 million US dollars (US$-PPP 10,324.2 million). The direct medical cost constituted the majority of the economic burden (64.7%), while the inability to work due to these health conditions also contributes significantly (28.6%). Absenteeism (2.9%), presenteeism (1.7%), and premature mortality (2.2%) make up smaller proportions of the overall economic impact of T2D and its complications in Iran during that year.
conclusionOur study highlights the significant and diverse economic impact of T2D and its complications in Iran. This burden encompasses not only healthcare-related expenses but also negative impacts on society and productivity, as well as the occurrence of early death. To successfully address this burden, a comprehensive strategy is needed, which includes programs to prevent diabetes, better access to healthcare services, and increased social support for individuals with this long-term condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.